Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Volume: 7, Issue: 1, Pages: 29 - 29
Published: Feb 4, 2019
Abstract
Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores...
Paper Details
Title
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
Published Date
Feb 4, 2019
Volume
7
Issue
1
Pages
29 - 29
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.